-DOCSTART- -X- O O 2066441

periodontal JJ 4_p
furcation NN 4_p
pockets NNS 4_p
. . 4_p

46 CD 4_p
upper JJ 4_p
and CC 4_p
lower JJR 4_p
molars NNS 4_p
with IN 4_p
furcation NN 4_p
grade NN 4_p
II NNP 4_p
involvement NN 4_p
16 CD 3_p
patients NNS 4_p
with IN 4_p
periodontal JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 23021296

patients NNS 4_p
with IN 4_p
depression NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
depression NN 4_p
. . 4_p

15 CD 3_p
depressive JJ 4_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
been VBN 4_p
under IN 4_p
antidepressant JJ 4_p
treatment NN 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
month NN 4_p
. . N

Depressive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 25931290

Children NNP 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNPS 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Participants NNS N
were VBD N
44 CD 3_p
children NNS 1_p
ages VBZ 1_p
6-12 NN 1_p
( ( N
n JJ 3_p
= $ 3_p
22 CD 3_p
typical JJ 3_p
, , 3_p
n JJ 3_p
= FW 3_p
22 CD 3_p
ASD NNP 3_p
) ) N
. . N

-DOCSTART- -X- O O 22416755

Preschoolers NNS 1_p
children NNS N
twenty-two JJ 3_p
3- JJ 1_p
to TO 1_p
4-year-olds NNS 1_p
thirty-two JJ 3_p
4- JJ 1_p
to TO 1_p
5-year-olds NNS 1_p
-DOCSTART- -X- O O 25886492

trial NN N
invited VBD N
25,511 CD 3_p
people NNS N
aged VBN 1_p
50-74 JJ 1_p
years NNS N
-DOCSTART- -X- O O 22420121

individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
individuals NNS 4_p
formally RB 4_p
diagnosed VBN 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

20 CD 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
( ( N
M NNP 1_p
age NN 1_p
= VBD 1_p
14.3 CD 1_p
yr. NN 1_p
SD NNP 1_p
= NNP 1_p
4.2 CD 1_p
; : N
6 CD 3_p
girls NNS N
, , N
14 CD 3_p
boys NNS N
) ) N
in IN N
the DT N
role NN N
of IN N
speakers NNS N
and CC N
20 CD 3_p
control NN N
children NNS 1_p
, , N
who WP N
acted VBD N
as IN N
listeners NNS N
. . N

Inclusion/exclusion NNP N
criteria NNS N
were VBD N
defined VBN N
according VBG N
to TO N
the DT N
clinical JJ N
diagnosis NN N
of IN N
ASD NNP N
, , N
the DT N
presence NN N
or CC N
absence NN N
of IN N
additional JJ N
or CC N
associated JJ N
disability NN N
, , N
previous JJ N
training NN N
in IN N
referential JJ N
communication NN N
, , N
and CC N
any DT N
drug NN N
treatment NN N
. . N

individuals NNS 4_p
with IN 4_p
ASD NNP 4_p
-DOCSTART- -X- O O 18189160

patients NNS 4_p
with IN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
: : 4_p
European NNP N
patients NNS 4_p
with IN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 11829043

patients NNS 4_p
after IN 4_p
stoma NN 4_p
surgery NN 4_p
. . 4_p

Eighteen JJ 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
undergone JJ 4_p
stoma NN 4_p
surgery NN 4_p
patients NNS 4_p
after IN 4_p
stoma NN 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 8779382

82 CD 3_p
patients NNS 4_p
having VBG 4_p
postoperative JJ 4_p
epidural JJ 4_p
analgesia NN 4_p
-DOCSTART- -X- O O 25068497

Cuban NNP N
pneumococcal JJ N
conjugate NN N
vaccine NN N
candidate NN N
in IN N
healthy JJ 4_p
children NNS 4_p
: : N
in IN N
4-5-year-old JJ 1_p
children NNS 1_p
-DOCSTART- -X- O O 22341427

infants NNS 1_p
with IN N
single-ventricle JJ 4_p
lesions NNS 4_p
: : N
infants NNS 1_p
undergoing VBG 4_p
the DT 4_p
Norwood NNP 4_p
procedure NN 4_p
549 CD 3_p
subjects NNS N
( ( N
follow-up JJ N
, , N
2.7 CD N
± JJ N
0.9 CD N
years NNS N
) ) N
-DOCSTART- -X- O O 21393467

human JJ 4_p
-DOCSTART- -X- O O 16055807

initial JJ 4_p
prodromal JJ 4_p
states NNS 4_p
of IN 4_p
psychosis NN 4_p
in IN N
Germany NNP 4_p
: : N
German JJ N
Schizophrenia NNP N
patients NNS N
in IN N
the DT N
" NNP 4_p
early JJ 4_p
initial JJ 4_p
prodromal JJ 4_p
state NN 4_p
" NN 4_p
. . N

patients NNS N
in IN N
the DT N
" NN 4_p
late JJ 4_p
initial JJ 4_p
prodromal JJ 4_p
state NN 4_p
" VBD 4_p
1212 CD 3_p
individuals NNS 4_p
seeking VBG 4_p
help NN 4_p
for IN 4_p
mental JJ 4_p
health NN 4_p
problems NNS 4_p
four CD N
university NN N
centres NNS N
. . N

More JJR 3_p
than IN 3_p
388 CD 3_p
individuals NNS 3_p
fulfilled VBD 3_p
criteria NNS 3_p
for IN 3_p
both DT 3_p
interventions NNS 3_p
and CC 3_p
188 CD 3_p
( ( 3_p
48.5 CD 3_p
% NN 3_p
) ) 3_p
gave VBD 3_p
informed VBN 3_p
consent NN 3_p
to TO 3_p
participate VB 3_p
in IN 3_p
the DT 3_p
trials NNS 3_p
. . 3_p

people NNS N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
psychosis NN N
. . N

-DOCSTART- -X- O O 7853069

primary JJ 4_p
care NN 4_p
patients NNS 4_p
with IN 4_p
untreated JJ 4_p
anxiety NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
previously RB 4_p
undetected VBN 4_p
anxiety NN 4_p
573 CD 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
unrecognized VBN 4_p
and CC 4_p
untreated JJ 4_p
anxiety NN 4_p
identified VBN N
from IN N
the DT N
approximately RB N
8,000 CD N
patients NNS N
who WP N
completed VBD N
the DT N
waiting VBG N
room NN N
screening NN N
questionnaire NN N
. . N

-DOCSTART- -X- O O 23357440

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
and CC 4_p
clinically RB 4_p
significant JJ 4_p
anxiety NN 4_p
. . N

45 CD 3_p
children NNS 1_p
( ( 1_p
7-11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
with IN N
high-functioning JJ 4_p
ASD NNP 4_p
and CC 4_p
clinically RB 4_p
significant JJ 4_p
anxiety NN 4_p
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 24515505

childhood NN 1_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
children NNS 1_p
aged VBD 1_p
3 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
, , N
with IN N
and CC N
without IN N
parent-reported JJ 4_p
ASD NNP 4_p
. . N

Children NNP 4_p
with IN 4_p
parent-reported JJ 4_p
ASD NNP 4_p
-DOCSTART- -X- O O 8771302

90 CD 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
aortic JJ 4_p
, , 4_p
mitral JJ 4_p
, , 4_p
and/or JJ 4_p
tricuspid JJ 4_p
valve FW 4_p
replacement NN 4_p
with IN 4_p
Sorin NNP 4_p
Bicarbon NNP 4_p
or CC 4_p
CarboMedics NNPS 4_p
bileaflet NN 4_p
prostheses NNS 4_p
. . N

-DOCSTART- -X- O O 21170734

Beluga NNP 4_p
, , 4_p
Huso NNP 4_p
huso NN 4_p
( ( 4_p
L. NNP 4_p
) ) 4_p
Beluga NNP 4_p
, , 4_p
Huso NNP 4_p
huso NN 4_p
( ( 4_p
L. NNP 4_p
) ) 4_p
for IN N
blood NN N
-DOCSTART- -X- O O 21211686

diabetic JJ 4_p
patients NNS 4_p
: : N
360 CD 3_p
diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
diabetic JJ 4_p
patients NNS 4_p
. . 4_p

diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 22154769

healthy JJ 4_p
adults NNS 1_p
≥60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
210 CD 3_p
subjects NNS N
≥60 CD 1_p
years NNS 1_p
immunogenic JJ N
in IN N
adults NNS N
≥60 CD N
-DOCSTART- -X- O O 21896676

The DT N
sample NN N
comprised VBD N
186 CD 3_p
patients NNS N
( ( N
mean JJ 1_p
age NN 1_p
70 CD 1_p
years NNS 1_p
, , N
123 CD 3_p
( ( N
66 CD N
% NN N
) ) N
female NN 2_p
patients NNS N
, , N
130 CD 3_p
( ( N
70 CD N
% NN N
) ) N
trauma NN 4_p
) ) N
who WP N
were VBD N
referred VBN 4_p
for IN 4_p
physiotherapy NN 4_p
assessment/intervention NN 4_p
. . N

-DOCSTART- -X- O O 20147856

chemo-naïve JJ 4_p
patients NNS N
with IN N
advanced JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
in IN N
chemo-naïve JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
patients NNS 4_p
METHODS NNP N
Patients NNPS N
with IN N
chemo-naïve JJ 4_p
stage NN 4_p
IIIB/IV NNP 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
RESULTS VB N
A DT N
total NN N
of IN N
80 CD 3_p
patients NNS N
were VBD N
entered VBN N
in IN N
this DT N
trial NN N
-DOCSTART- -X- O O 6920252

the DT 4_p
premature NN 4_p
monkey NN 4_p
: : 4_p
premature NN 4_p
monkey NN 4_p
( ( 4_p
Macaca NNP 4_p
nemestrina RB 4_p
) ) 4_p
model NN 4_p
of IN 4_p
hyaline JJ 4_p
membrane NN 4_p
disease NN 4_p
( ( 4_p
HMD NNP 4_p
) ) 4_p
. . 4_p

Twelve NNP 3_p
dams VBZ 3_p
Twelve VB 3_p
control NN 3_p
animals NNS 3_p
in IN N
this DT N
animal JJ N
model NN N
; : N
-DOCSTART- -X- O O 12960652

infants NNS 1_p
with IN N
gastrointestinal JJ 4_p
diseases NNS 4_p
control NN N
infants NNS N
, , N
compared VBN N
to TO N
infants NNS 4_p
with IN 4_p
different JJ 4_p
gastrointestinal JJ 4_p
diseases NNS 4_p
, , N
before IN N
and CC N
after IN N
treatment NN N
of IN N
their PRP$ N
disease NN N
. . N

21 CD 3_p
patients NNS 4_p
( ( N
age NN 1_p
0-2 CD 1_p
months NNS 1_p
) ) N
and CC N
40 CD 3_p
healthy JJ 4_p
infants NNS 1_p
( ( N
age NN 1_p
0-2 CD 1_p
months NNS 1_p
) ) N
patients NNS 4_p
suffered VBD 4_p
from IN 4_p
partial JJ 4_p
or CC 4_p
total JJ 4_p
intestinal JJ 4_p
obstruction NN 4_p
, , 4_p
necrotizing VBG 4_p
enterocolitis NN 4_p
or CC 4_p
pyloric JJ 4_p
stenosis.All NN 4_p
infants NNS 4_p
were VBD 4_p
fasting VBG 4_p
infants NNS N
with IN N
partial JJ N
or CC N
total JJ N
intestinal JJ N
obstruction NN N
-DOCSTART- -X- O O 8913901

patients NNS 4_p
with IN 4_p
multivessel JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
4,244 CD 3_p
BARI NNP N
randomized VBN N
and CC N
registry NN 4_p
study NN 4_p
participants NNS 4_p
with IN 4_p
follow-up JJ 4_p
ECGs NNP 4_p
received VBD 4_p
at IN 4_p
the DT 4_p
Core NNP 4_p
ECG NNP 4_p
Laboratory NNP 4_p
as IN 4_p
of IN 4_p
March NNP 4_p
1995 CD 4_p
-DOCSTART- -X- O O 22881991

young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
with IN 4_p
a DT 4_p
range NN 4_p
of IN 4_p
intellectual JJ 4_p
ability NN 4_p
. . N

Participants NNPS N
were VBD N
55 CD 3_p
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
, , N
aged VBN 1_p
4-7 CD 1_p
years NNS 1_p
( ( N
FSIQ NNP N
42-107 CD N
) ) N
. . N

young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
-DOCSTART- -X- O O 7814711

Staphylococcus NNP N
aureus NN N
mastitis NN N
. . N

Staphylococcus NNP N
aureus NN N
mastitis NN N
, , N
37 CD 3_p
Holstein NNP 4_p
cows NNS 4_p
-DOCSTART- -X- O O 20509069

physical JJ 4_p
trauma NN 4_p
. . 4_p

21 CD 3_p
hospitalized JJ 4_p
trauma NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 24989854

preadolescent JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASDs NNP 4_p
) ) 4_p
children NNS 4_p
with IN 4_p
ASD NNP 4_p
120 CD 3_p
participants NNS 4_p
with IN 4_p
ASD NNP 4_p
at IN 4_p
the DT 4_p
end NN 4_p
of IN 4_p
primary JJ 4_p
school NN 4_p
( ( N
10-12 CD 1_p
years NNS 1_p
of IN 1_p
calendar NN 1_p
age NN 1_p
) ) N
Dutch NNP 4_p
children NNS 1_p
with IN 4_p
ASD NNP 4_p
in IN 4_p
a DT 4_p
specific JJ 1_p
age NN 1_p
range NN 1_p
( ( 1_p
10-12 CD 1_p
years NNS 1_p
) ) 1_p
. . 4_p

-DOCSTART- -X- O O 22865017

PTSD NNP 4_p
patients NNS 4_p
with IN 4_p
Posttraumatic NNP 4_p
stress NN 4_p
disorder NN 4_p
( ( 4_p
PTSD NNP 4_p
) ) 4_p
. . 4_p

PTSD NNP N
PTSD JJ 4_p
patients NNS N
were VBD N
recruited VBN N
from IN N
five CD 4_p
primary JJ 4_p
care NN 4_p
clinics NNS 4_p
at IN 4_p
four CD 4_p
Veterans NNS 4_p
Affairs NNP 4_p
healthcare NN 4_p
facilities NNS 4_p
Participants NNS N
were VBD N
195 CD 3_p
Veterans NNPS 4_p
. . N

Their PRP$ N
average JJ 1_p
age NN 1_p
was VBD 1_p
45 CD 1_p
years NNS 1_p
, , N
91 CD 1_p
% NN 1_p
were VBD 1_p
male JJ 2_p
, , N
58 CD N
% NN N
were VBD N
white JJ N
, , N
40 CD N
% NN N
served VBN N
in IN N
Iraq NNP N
or CC N
Afghanistan NNP N
, , N
and CC N
42 CD N
% NN N
served VBD N
in IN N
Vietnam NNP N
. . N

-DOCSTART- -X- O O 18958161

individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

Children NNP 1_p
with IN N
ASD NNP 4_p
and CC 4_p
typically RB 4_p
developing VBG 4_p
( ( 4_p
TD NNP 4_p
) ) 4_p
children NNS 4_p
-DOCSTART- -X- O O 21982657

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
HF NNP 4_p
) ) 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
class NN 4_p
II NNP 4_p
to TO 4_p
IV NNP 4_p
HF NNP 4_p
and CC 4_p
ejection NN 4_p
fraction NN 4_p
< VBD 4_p
35 CD 4_p
% NN 4_p
. . 4_p

Of IN N
330 CD 3_p
patients NNS N
intended VBN N
for IN N
enrollment NN N
, , N
23 CD 3_p
were VBD N
randomized VBN N
( ( N
MARVEL-1 NNP N
) ) N
before IN N
stopping VBG N
the DT N
study NN N
for IN N
financial JJ N
reasons NNS N
. . N

In IN N
HF NNP N
patients NNS N
with IN N
chronic JJ N
postinfarction NN N
cardiomyopathy NN N
in IN N
HF NNP N
patients NNS N
with IN N
postinfarction NN N
cardiomyopathy NN N
-DOCSTART- -X- O O 19376304

patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
( ( N
AF NNP 4_p
) ) N
patients NNS N
with IN N
nonvalvular JJ N
AF NNP N
and CC N
at IN N
least JJS N
1 CD N
risk NN N
factor NN N
for IN N
stroke NN N
. . N

Recruitment NNP N
concluded VBD N
with IN N
a DT N
total NN N
of IN N
18,113 CD 3_p
patients NNS N
. . N

Patients NNS N
who WP N
were VBD N
VKA-naive NNP N
and CC N
experienced VBN N
are VBP N
included VBN N
in IN N
balanced JJ N
proportions NNS N
. . N

-DOCSTART- -X- O O 2908133

anxiety NN 4_p
: : 4_p
92 CD 3_p
outpatients NNS 4_p
affected VBN 4_p
by IN 4_p
generalized JJ 4_p
anxiety NN 4_p
disorders NNS 4_p
Seventy-eight JJ 3_p
patients NNS N
completed VBD N
the DT N
first JJ N
period NN N
and CC N
75 CD 3_p
the DT N
whole NN N
study NN N
. . N

-DOCSTART- -X- O O 10752495

patients NNS 4_p
with IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
. . 4_p

38 CD 3_p
patients NNS 3_p
with IN 3_p
RA NNP 3_p
and CC N
20 CD 3_p
controls NNS 3_p
. . N

controls NNS N
RA NNP N
patients NNS N
in IN N
RA NNP N
. . N

RA NNP N
group NN N
RA NNP N
-DOCSTART- -X- O O 21924760

atrial JJ 4_p
fibrillation NN 4_p
patients NNS 4_p
: : 4_p
ACTIVE NNP 4_p
W NNP 4_p
study NN 4_p
patients NNS 4_p
, , 4_p
cases NNS 4_p
with IN 4_p
stroke NN 4_p
and CC 4_p
cases NNS 4_p
with IN 4_p
bleeding NN 4_p
were VBD 4_p
separately RB 4_p
matched VBN 4_p
with IN 4_p
controls NNS 4_p
. . 4_p

32 CD 3_p
cases NNS 4_p
with IN 4_p
ischemic JJ 4_p
stroke NN 4_p
and CC N
234 CD 3_p
cases NNS 4_p
with IN 4_p
bleeding NN 4_p
in IN N
the DT N
analysis NN N
were VBD N
matched VBN N
122 CD N
and CC N
865 CD N
controls NNS N
lower JJR N
in IN N
individual JJ N
AF NNP N
patients NNS N
-DOCSTART- -X- O O 11454878

Recurrent JJ N
epithelial JJ N
ovarian JJ N
carcinoma NN N
: : N
patients NNS 4_p
with IN 4_p
epithelial JJ 4_p
ovarian JJ 4_p
carcinoma NN 4_p
that WDT 4_p
recurred VBD 4_p
after IN 4_p
or CC 4_p
did VBD 4_p
n't RB 4_p
respond VB 4_p
to TO 4_p
first-line JJ 4_p
, , 4_p
platinum-based JJ 4_p
chemotherapy NN 4_p
. . 4_p

Patients NNPS 4_p
with IN 4_p
measurable JJ 4_p
and CC 4_p
assessable JJ 4_p
disease NN 4_p
A DT N
total NN N
of IN N
474 CD 3_p
patients NNS N
were VBD N
treated VBN N
-DOCSTART- -X- O O 21866656

endometriosis-related JJ 4_p
infertility NN 4_p
patients NNS 4_p
endometriosis NN 4_p
( ( 4_p
EMs NNP 4_p
) ) 4_p
-related VBD 4_p
infertility NN 4_p
patients NNS 4_p
. . 4_p

130 CD 3_p
EMs-related JJ 4_p
infertility NN 4_p
patients NNS 4_p
of IN N
blood NN 4_p
stasis NN 4_p
and CC 4_p
toxin NN 4_p
accumulation NN 4_p
syndrome NN 4_p
diagnosed VBD 4_p
and CC 4_p
treated VBN 4_p
by IN 4_p
laparoscopic NN 4_p
surgery NN 4_p
EMs NNP N
patients NNS N
of IN N
blood NN N
stasis NN N
and CC N
toxin NN N
accumulation NN N
syndrome NN N
EMs-related JJ N
infertility NN N
. . N

-DOCSTART- -X- O O 3067745

Fifty-one CD 3_p
patients NNS 4_p
with IN N
raised VBN 4_p
intraocular JJ 4_p
pressure NN 4_p
( ( 4_p
IOP NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 24350813

children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorders NNS 4_p
. . N

patients NNS N
( ( N
5-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
who WP N
completed VBD N
the DT N
previous JJ N
fixed-dose JJ N
, , N
6 CD N
week NN N
, , N
double-blind JJ N
[ NNP N
DB NNP N
] NNP N
phase NN N
) ) N
RESULTS VB N
Fifty-six NNP N
( ( N
71 CD N
% NN N
) ) N
out IN N
of IN N
79 CD N
enrolled JJ N
patients NNS N
completed VBD N
the DT N
OLE NNP N
; : N
-DOCSTART- -X- O O 22646975

patients NNS 4_p
with IN 4_p
inflammatory JJ 4_p
bowel NN 4_p
disease NN 4_p
. . 4_p

Fifty-six JJ 3_p
outpatients NNS 3_p
Thirty-nine JJ 3_p
subjects NNS 3_p
completed VBD 3_p
the DT 3_p
study NN 3_p
-DOCSTART- -X- O O 2223363

elderly JJ 1_p
patients NNS 1_p
. . 1_p

60 CD 3_p
elderly JJ 1_p
patients NNS 1_p
. . N

-DOCSTART- -X- O O 20943715

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
stroke NN 4_p
. . 4_p

Fifteen NNP 3_p
subjects VBZ 4_p
with IN 4_p
post-stroke JJ 4_p
hemiparesis NN 4_p
. . N

performance NN N
of IN N
patients NNS N
with IN N
post-stroke JJ 4_p
hemiparesis NN 4_p
-DOCSTART- -X- O O 18503531

children NNS 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
: : N
children NNS 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
: : N
Forty-nine JJ 3_p
children NNS 4_p
with IN 4_p
AS NNP 4_p
children NNS 4_p
with IN 4_p
AS NNP 4_p
. . 4_p

-DOCSTART- -X- O O 20804366

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

50 CD 3_p
children NNS 1_p
. . N

children NNS N
. . N

children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 20560622

male JJ 2_p
adolescents NNS 2_p
adolescents NNS 1_p
18 CD 3_p
male NN 2_p
adolescents NNS 1_p
-DOCSTART- -X- O O 21029638

schizophrenics NNS 4_p
: : N
schizophrenics NNS 4_p
. . 4_p

total NN N
of IN N
81 CD 3_p
schizophrenics NNS 4_p
and CC N
psychiatric JJ N
-DOCSTART- -X- O O 18845996

metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
( ( 4_p
MBC NNP 4_p
) ) 4_p
. . 4_p

MBC NNP N
( ( N
n JJ N
= NNP N
509 CD N
) ) N
MBC NNP N
patients NNS 4_p
-DOCSTART- -X- O O 12586799

advanced JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
NPC NNP 4_p
. . 4_p

From NNP 4_p
December NNP 4_p
1993 CD 4_p
to TO 4_p
April NNP 4_p
1999 CD 4_p
, , N
284 CD 3_p
patients NNS 4_p
with IN 4_p
1992 CD 4_p
American NNP 4_p
Joint NNP 4_p
Committee NNP 4_p
on IN 4_p
Cancer NNP 4_p
stage NN 4_p
III NNP 4_p
to TO 4_p
IV NNP 4_p
( ( 4_p
M0 NNP 4_p
) ) 4_p
NPC NNP 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
NPC NNP 4_p
in IN N
endemic JJ N
areas NNS N
. . N

-DOCSTART- -X- O O 22271197

autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 23103798

refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
: : N
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
. . N

28 CD 3_p
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
. . N

-DOCSTART- -X- O O 7598243

major JJ N
gynecologic NN N
surgery NN N
. . N

360 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I-III NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
total JJ 4_p
abdominal JJ 4_p
hysterectomy NN 4_p
( ( 4_p
TAH NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 25479285

cardiovascular VB N
preventive JJ N
treatment NN N
303 CD 3_p
patients NNS 4_p
taking VBG 4_p
blood NN 4_p
pressure NN 4_p
and/or IN 4_p
lipid-lowering JJ 4_p
medications NNS 4_p
-DOCSTART- -X- O O 24960665

Tunisians NNS 4_p
: : 4_p
370 CD 3_p
RH:1 NNP 4_p
Tunisian JJ 3_p
donors NNS 3_p
370 CD 3_p
donors NNS 3_p
Tunisians NNPS N
. . N

-DOCSTART- -X- O O 15854186

flexible JJ 4_p
nasendoscopy NN 4_p
: : 4_p
98 CD 3_p
patients NNS 3_p
flexible JJ 4_p
nasendoscopy NN 4_p
. . 4_p

flexible JJ 4_p
nasendoscopy NN 4_p
. . 4_p

-DOCSTART- -X- O O 2088233

localized VBN 4_p
juvenile NN 4_p
periodontitis NN 4_p
. . 4_p

16 CD 3_p
patients NNS 4_p
with IN 4_p
localized JJ 4_p
juvenile NN 4_p
periodontitis NN 4_p
. . N

patients NNS 4_p
with IN 4_p
localized JJ 4_p
juvenile NN 4_p
periodontitis NN 4_p
. . 4_p

-DOCSTART- -X- O O 1968178

ten JJ 3_p
normotensive JJ 4_p
and CC N
seven CD 3_p
hypertensive JJ 4_p
subjects NNS N
( ( N
hypertensive JJ N
and CC N
normotensive JJ N
subjects NNS N
-DOCSTART- -X- O O 10764172

abdominal JJ N
surgery NN N
. . N

patients NNS N
who WP N
underwent JJ 4_p
hysterectomy NN 4_p
. . N

Forty NNP 3_p
patients NNS 3_p
were VBD 3_p
divided VBN 3_p
into IN 3_p
four CD 3_p
groups NNS 3_p
of IN 3_p
ten NN 3_p
. . 3_p

abdominal JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 9394106

patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
-- : N
a DT N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
. . 4_p

Fifty JJ 3_p
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
( ( 4_p
27 CD 3_p
with IN 4_p
cirrhosis NN 4_p
, , 4_p
23 CD 3_p
without IN 4_p
cirrhosis NN 4_p
) ) 4_p
15 CD 3_p
healthy JJ 4_p
controls NNS 4_p
. . N

patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 10475150

healthy JJ 4_p
volunteers NNS 4_p
and CC 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypothyroidism NN 4_p
. . 4_p

8 CD 3_p
healthy JJ 4_p
volunteers NNS 4_p
, , N
and CC N
6 CD 3_p
women NNS 2_p
with IN N
untreated JJ 4_p
primary JJ 4_p
hypothyroidism NN 4_p
healthy JJ 4_p
volunteers NNS 4_p
healthy JJ N
controls NNS N
The DT N
patients NNS 4_p
with IN 4_p
hypothyroidism NN 4_p
normal JJ 4_p
subjects NNS 4_p
and CC 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypothyroidism NN 4_p
-DOCSTART- -X- O O 7017018

in IN N
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
. . N

75 CD 3_p
children NNS 1_p
after IN 4_p
renal JJ 4_p
transplantation NN 4_p
-DOCSTART- -X- O O 19301724

after IN N
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
( ( 4_p
TKA NNP 4_p
) ) 4_p
. . 4_p

61 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I-III NNP 4_p
patients NNS 4_p
scheduled VBN 4_p
for IN 4_p
elective JJ 4_p
unilateral JJ 4_p
total NN 4_p
knee NN 4_p
arthroplasty NN 4_p
( ( 4_p
TKA NNP 4_p
) ) 4_p
under IN 4_p
spinal JJ 4_p
anesthesia NN 4_p
( ( 4_p
SA NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 18975051

10 CD 3_p
patients NNS 3_p
in IN 3_p
each DT 3_p
group NN 3_p
. . 3_p

-DOCSTART- -X- O O 9730996

severe JJ 4_p
bronchiectasis NN 4_p
. . 4_p

bronchiectasis NN N
. . N

Twenty-four CD 3_p
patients NNS N
( ( N
12 CD 3_p
female NN N
; : N
mean JJ 1_p
age NN 1_p
51 CD 1_p
yr NN 1_p
) ) N
bronchiectasis NN N
. . N

bronchiectasis NN 4_p
. . 4_p

-DOCSTART- -X- O O 8911223

adults NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
. . 4_p

Thirty NNP 3_p
adults NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
autistic JJ N
disorder NN N
in IN N
adults NNS N
. . N

-DOCSTART- -X- O O 1131298

10 CD 3_p
healthy JJ 4_p
subjects NNS 4_p
. . N

-DOCSTART- -X- O O 7707420

first-degree JJ 4_p
relatives NNS 4_p
of IN 4_p
index NN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
200 CD 3_p
women NNS 2_p
aged VBN 1_p
35 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
who WP N
had VBD N
a DT N
family NN 4_p
history NN 4_p
of IN 4_p
breast NN 4_p
cancer NN 4_p
in IN 4_p
a DT 4_p
first-degree JJ 4_p
relative NN 4_p
. . N

Women NNS 4_p
with IN N
a DT N
personal JJ 4_p
history NN 4_p
of IN 4_p
cancer NN 4_p
were VBD N
excluded VBN N
. . N

-DOCSTART- -X- O O 15848261

stroke NN 4_p
patients NNS 4_p
] VBP 4_p
post-acute JJ 4_p
hemiparetic JJ 4_p
patients NNS 4_p
Twenty-six JJ 3_p
patients NNS 4_p
within IN 4_p
3 CD 4_p
months NNS 4_p
of IN 4_p
onset NN 4_p
of IN 4_p
stroke NN 4_p
-DOCSTART- -X- O O 6418441

asthma NN 4_p
in IN N
adults NNS 1_p
31 CD 3_p
adult NN 1_p
asthmatic JJ 4_p
patients NNS N
-DOCSTART- -X- O O 9573502

patients NNS 4_p
with IN 4_p
hemodynamically RB 4_p
decompensated VBN 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

16 CD 3_p
decompensated JJ 4_p
heart NN 4_p
failure NN 4_p
patients NNS 4_p
decompensated JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O 7827398

elderly JJ 1_p
patients NNS 1_p
in IN N
older JJR 1_p
patients NNS 1_p
. . N

Old NNP 4_p
Patients NNPS 4_p
with IN 4_p
Hypertension NNP 4_p
older JJR 4_p
patients NNS 4_p
( ( 4_p
> JJ 4_p
60 CD 4_p
years NNS 4_p
) ) 4_p
with IN 4_p
both DT 4_p
diastolic JJ 4_p
and CC 4_p
isolated JJ 4_p
systolic JJ 4_p
hypertension NN 4_p
. . 4_p

older JJR N
patients NNS N
. . N

older JJR 4_p
individuals NNS 4_p
with IN 4_p
hypertension NN 4_p
. . 4_p

-DOCSTART- -X- O O 1459268

in IN N
vitro JJ N
fertilization NN N
in IN 4_p
vitro JJ 4_p
fertilization NN 4_p
( ( 4_p
IVF NNP 4_p
) ) 4_p
Aberdeen NNP N
Assisted NNP N
Reproduction NNP N
Unit NNP N
. . N

Forty-eight JJ 3_p
patients NNS 4_p
having VBG 4_p
IVF NNP 4_p
for IN 4_p
the DT 4_p
first JJ 4_p
time NN 4_p
patients NNS N
undergoing VBG 4_p
IVF NNP 4_p
. . N

-DOCSTART- -X- O O 1963383

small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
] NNP 4_p
Eighty-three JJ 3_p
patients NNS 4_p
with IN 4_p
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
74 CD 3_p
patients NNS 3_p
solid JJ 4_p
cancer NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 25885649

rheumatoid JJ 4_p
arthritis NN 4_p
patients NNS 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
RA NNP N
patients NNS N
' POS N
Sixty-eight JJ 3_p
RA NNP 4_p
patients NNS N
( ( N
age=55±13 JJ 1_p
years NNS 1_p
, , N
body NN N
mass NN N
index NN N
: : N
27.8±5.4 CD N
kg/m2 NN N
, , N
median NN N
of IN N
disease NN N
duration=5 NN N
( ( N
2-8 JJ N
) ) N
yrs NN N
) ) N
in IN N
people NNS N
with IN N
RA NNP N
-DOCSTART- -X- O O 3074300

non-insulin JJ 4_p
dependent NN 4_p
diabetes VBZ 4_p
mellitus NN 4_p
. . 4_p

30 CD 3_p
non-insulin JJ 4_p
dependent NN 4_p
( ( 4_p
Type NNP 4_p
II NNP 4_p
) ) 4_p
diabetic JJ 4_p
subjects NNS 4_p
Type NNP N
II NNP N
diabetes VBZ N
. . N

Type NNP 4_p
II NNP 4_p
diabetic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 20226474

endobronchial JJ 4_p
tumor NN 4_p
lesions NNS 4_p
. . 4_p

296 CD 3_p
patients NNS 4_p
with IN 4_p
visible JJ 4_p
endoluminal JJ 4_p
tumor NN 4_p
lesions NNS 4_p
were VBD 4_p
included VBN 4_p
bronchoscopy NN 4_p
unit NN 4_p
of IN 4_p
a DT 4_p
university NN 4_p
hospital NN 4_p
. . 4_p

-DOCSTART- -X- O O 19802506

postmenopausal JJ 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
with IN 4_p
bone JJ 4_p
loss NN 4_p
: : 4_p
223 CD 3_p
postmenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
. . N

postmenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
( ( 4_p
BCS NNP 4_p
) ) 4_p
with IN 4_p
bone NN 4_p
loss NN 4_p
Postmenopausal NNP 4_p
BCS NNP 4_p
( ( N
223 CD 3_p
) ) N
postmenopausal NN N
BCS NNP N
at IN N
risk NN N
for IN N
bone NN N
loss NN N
. . N

-DOCSTART- -X- O O 1669598

asthma NN N
due JJ N
to TO N
house NN N
dust NN N
mite NN N
Dermatophagoides NNP N
pteronyssinus NN N
: : N
10 CD 3_p
patients NNS 4_p
with IN 4_p
asthma NNS 4_p
due JJ 4_p
to TO 4_p
HDM NNP 4_p
asthma NNS N
due JJ N
to TO N
HDM NNP N
. . N

-DOCSTART- -X- O O 15358868

adults NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

adults NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

adults NNS 4_p
with IN 4_p
autism NN 4_p
adults NNS N
with IN N
autism NN N
adults NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 4919024

391 CD 3_p
medical JJ 4_p
student NN 4_p
volunteers NNS 4_p
during IN 4_p
the DT 4_p
influenza JJ 4_p
A2 NNP 4_p
Hong NNP 4_p
Kong NNP 4_p
epidemic VBP 4_p
in IN 4_p
Helsinki NNP 4_p
in IN 4_p
the DT 4_p
winter NN 4_p
of IN 4_p
1969 CD 4_p
. . N

-DOCSTART- -X- O O 16427787

human JJ 4_p
-DOCSTART- -X- O O 15193668

peers NNS 4_p
' POS N
peers NNS 4_p
' POS N
child NN 4_p
with IN 4_p
autism NN 4_p
. . 4_p

Children NNP 1_p
( ( N
N NNP N
= NNP N
576 CD 3_p
; : N
M NNP 1_p
age NN 1_p
= VBD 1_p
10.06 CD 1_p
) ) N
children NNS 1_p
's POS 1_p
-DOCSTART- -X- O O 23356250

sickle NN 4_p
cell NN 4_p
anemia NN 4_p
. . 4_p

sickle NN N
cell NN N
anemia NN N
( ( N
SCA NNP N
) ) N
children NNS 1_p
with IN N
SCA NNP 4_p
113 CD 3_p
children NNS 1_p
with IN N
SCA NNP 4_p
studied VBN N
in IN N
two CD N
hospitals NNS N
in IN N
children NNS 1_p
with IN N
SCA NNP 4_p
-DOCSTART- -X- O O 24726342

stable JJ 4_p
COPD NNP 4_p
patients NNS 4_p
. . 4_p

COPD NNP 4_p
patients NNS 4_p
days NNS N
, , N
60 CD 3_p
COPD NNP 4_p
patients NNS N
-DOCSTART- -X- O O 11381289

patients NNS 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
cardiovascular JJ 4_p
events NNS 4_p
. . 4_p

-DOCSTART- -X- O O 20739054

chronic JJ 4_p
immune NN 4_p
thrombocytopenia NN 4_p
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
immune JJ 4_p
thrombocytopenia NN 4_p
adults NNS 1_p
with IN N
previously RB 4_p
treated VBN 4_p
immune JJ 4_p
thrombocytopenia NN 4_p
of IN 4_p
more JJR 4_p
than IN 4_p
6 CD 4_p
months NNS 4_p
' POS 4_p
duration NN 4_p
who WP N
had VBD N
baseline NN 4_p
platelet NN 4_p
counts VBZ 4_p
lower JJR 4_p
than IN 4_p
30,000 CD 4_p
per IN 4_p
μL NN 4_p
FINDINGS NNP N
Between NNP N
Nov NNP N
22 CD N
, , N
2006 CD N
, , N
and CC N
July NNP N
31 CD N
, , N
2007 CD N
, , N
197 CD 3_p
patients NNS N
-DOCSTART- -X- O O 18773733

Vibrotactile NNP N
-- : N
auditory JJ N
interactions NNS N
auditory JJ N
stimulation NN N
-DOCSTART- -X- O O 24803369

Youth NN 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
Individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
13 CD 3_p
participants NNS 4_p
with IN 4_p
ASD NNP 4_p
( ( N
age NN 1_p
7 CD 1_p
; : 1_p
03-22 CD 1_p
; : 1_p
03 CD 1_p
) ) N
and CC N
13 CD 3_p
age-matched JJ 4_p
typically RB 4_p
developing VBG 4_p
( ( 4_p
TD NNP 4_p
) ) 4_p
controls NNS 4_p
Individuals NNS 4_p
with IN 4_p
ASD NNP 4_p
-DOCSTART- -X- O O 14679127

advanced JJ 4_p
epithelial JJ 4_p
ovarian JJ 4_p
carcinoma NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
epithelial JJ 4_p
ovarian JJ 4_p
cancer NN 4_p
who WP 4_p
had VBD 4_p
failed VBN 4_p
one CD 4_p
prior JJ 4_p
platinum-based JJ 4_p
regimen NNS 4_p
. . 4_p

Patients NNPS 4_p
with IN 4_p
bidimensionally RB 4_p
measurable JJ 4_p
disease NN 4_p
A DT N
total NN N
of IN N
226 CD 3_p
patients NNS N
were VBD N
evaluable JJ N
for IN N
response NN N
. . N

ovarian JJ 4_p
cancer NN 4_p
. . 4_p

-DOCSTART- -X- O O 11642083

patients NNS 4_p
on IN 4_p
thrombolytic JJ 4_p
therapy NN 4_p
( ( 4_p
TLT NNP 4_p
) ) 4_p
. . 4_p

106 CD 3_p
males NNS 2_p
with IN N
Q-MI NNP 4_p
entered VBD N
the DT N
study NN N
. . N

MI NNP N
patients NNS N
receiving VBG N
TLT NNP N
-DOCSTART- -X- O O 25784723

children NNS 1_p
and CC 1_p
young JJ 1_p
adults NNS 4_p
after IN 4_p
repair NN 4_p
of IN 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NN 4_p
: : N
patients NNS 4_p
with IN 4_p
corrected JJ 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NNP 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NNP 4_p
aged VBD 1_p
10 CD 1_p
to TO 1_p
25 CD 1_p
years NNS 1_p
. . N

training NN N
in IN N
children NNS N
and CC N
young JJ N
adults NNS N
with IN N
repaired JJ N
tetralogy NN N
of IN N
Fallot NNP N
-DOCSTART- -X- O O 2678230

16 CD 3_p
patients NNS 4_p
with IN 4_p
ischaemic JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 2188766

congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

Seventeen JJ 3_p
patients NNS 4_p
on IN 4_p
chronic JJ 4_p
digitalis NN 4_p
and CC 4_p
diuretic JJ 4_p
therapy NN 4_p
patients NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

-DOCSTART- -X- O O 22538329

patients NNS 4_p
with IN 4_p
spotty JJ 4_p
calcification NN 4_p
. . 4_p

A NNP N
total NN N
of IN N
1,347 CD 3_p
stable JJ 4_p
patients NNS 4_p
with IN 4_p
angiographic JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
Patients NNS N
with IN N
spotty JJ N
calcification NN N
were VBD N
identified VBN N
based VBN N
on IN N
the DT N
presence NN N
of IN N
lesions NNS N
( ( N
1 CD N
to TO N
4 CD N
mm NNS N
in IN N
length NN N
) ) N
containing VBG N
an DT N
arc NN N
of IN N
calcification NN N
of IN N
< $ N
90° CD N
RESULTS JJ N
Patients NNS N
with IN N
spotty JJ N
calcification NN N
were VBD N
older JJR N
( ( N
age NN N
56 CD N
years NNS N
vs. IN N
54 CD N
years NNS N
; : N
p VBZ N
= $ N
0.001 CD N
) ) N
, , N
more RBR N
likely JJ N
to TO N
be VB N
male JJ N
( ( N
68 CD N
% NN N
vs. FW N
54 CD N
% NN N
; : N
0.001 CD N
) ) N
attenuated VBN N
in IN N
patients NNS N
with IN N
spotty JJ N
calcification NN N
-DOCSTART- -X- O O 22956006

for IN N
breast NN 4_p
cancer NN 4_p
if IN N
patients NNS N
receiving VBG N
chemotherapy NN N
for IN N
breast NN 4_p
cancer NN 4_p
for IN N
chemotherapy-naïve JJ 4_p
patients NNS 4_p
with IN 4_p
breast JJ 4_p
cancer NN 4_p
to TO N
8 CD N
. . N

Median JJ N
age NN N
of IN N
the DT N
94 CD 3_p
women NNS 2_p
was VBD N
51 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
27-76 JJ 1_p
) ) 1_p
: : N
-DOCSTART- -X- O O 15858959

children NNS 1_p
with IN N
acute JJ 4_p
diarrhoea NN 4_p
. . N

acute JJ N
childhood NN N
diarrhoea NN N
children NNS 4_p
with IN 4_p
acute JJ 4_p
diarrhoea NN 4_p
. . 4_p

Two CD 3_p
hundred VBD 3_p
children NNS 3_p
acute JJ 4_p
diarrhoea NN 4_p
in IN 4_p
children NNS 4_p
-DOCSTART- -X- O O 19727232

autistic JJ 4_p
children NNS 1_p
] VBP N
autistic JJ 4_p
children NNS 1_p
81 CD 3_p
cases NNS 4_p
of IN 4_p
autistic JJ 4_p
children NNS 4_p
were VBD N
selected VBN N
autistic JJ 4_p
children NNS 4_p
-DOCSTART- -X- O O 1286547

borderline JJ 4_p
hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
IDDM-type NNP 4_p
diabetes NNS 4_p
mellitus NN 4_p
. . 4_p

Twenty-nine JJ 3_p
IDDM NNP 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
hypertension NN 4_p
diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
hypertension NN 4_p
. . 4_p

-DOCSTART- -X- O O 12595499

in IN N
people NNS 4_p
at IN 4_p
high JJ 4_p
cardiovascular JJ 4_p
risk NN 4_p
: : N
people NNS 4_p
with IN 4_p
diabetes NNS 4_p
7674 CD 3_p
participants NNS 4_p
with IN 4_p
albuminuria NNS 4_p
data NNS 4_p
at IN 4_p
baseline NN 4_p
and CC 4_p
at IN 4_p
follow-up JJ 4_p
. . N

Inclusion NN N
criteria NNS N
were VBD N
known VBN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
plus CC N
one CD N
other JJ N
cardiovascular JJ N
risk NN N
factor NN N
, , N
exclusion NN N
criteria NNS N
included VBD N
heart NN N
failure NN N
or CC N
known VBN N
impaired JJ N
left VBD N
ventricular JJ N
function NN N
, , N
dipstick-positive JJ N
proteinuria NN N
( ( N
> JJ N
1+ CD N
) ) N
, , N
and CC N
serum JJ N
creatinine NN N
> $ N
2.3 CD N
mg/dl NN N
( ( N
200 CD N
microM NN N
) ) N
. . N

People NNS N
without IN N
and CC N
with IN N
diabetes NNS N
who WP N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
nondiabetic JJ 4_p
and CC 4_p
in IN 4_p
diabetic JJ 4_p
people NNS 4_p
. . 4_p

-DOCSTART- -X- O O 11401641

patients NNS 4_p
insufficiently RB 4_p
controlled VBN 4_p
on IN 4_p
timolol NN 4_p
. . 4_p

in IN N
patients NNS 4_p
with IN 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
where WRB 4_p
IOP NNP 4_p
is VBZ 4_p
not RB 4_p
adequately RB 4_p
controlled VBN 4_p
with IN 4_p
timolol NN 4_p
. . 4_p

53 CD 3_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
, , 4_p
capsular JJ 4_p
glaucoma NN 4_p
, , 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
with IN 4_p
an DT 4_p
IOP NNP 4_p
of IN 4_p
at IN 4_p
least JJS 4_p
21 CD 4_p
mmHg NN 4_p
on IN 4_p
current JJ 4_p
therapy NN 4_p
-DOCSTART- -X- O O 14739125

healthy JJ 4_p
young JJ 1_p
subjects NNS N
Five NNP 3_p
groups NNS 3_p
of IN 3_p
8 CD 3_p
subjects NNS 3_p
each DT 3_p
-DOCSTART- -X- O O 10589810

supportive JJ N
periodontal JJ N
therapy NN N
( ( N
SPT NNP N
) ) N
. . N

during IN N
supportive JJ N
periodontal JJ N
therapy NN N
. . N

40 CD 3_p
subjects NNS 3_p
-DOCSTART- -X- O O 7808649

patients NNS 4_p
suffering VBG 4_p
from IN 4_p
post-operative JJ 4_p
pain NN 4_p
after IN 4_p
cholecystectomy NN 4_p
. . 4_p

99 CD 3_p
patients NNS 4_p
with IN 4_p
severe JJ 4_p
pain NN 4_p
following VBG 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 8916620

Analysis NN N
of IN N
prevention NN 4_p
program NN 4_p
effectiveness NN N
with IN N
clustered VBN N
data NNS N
using VBG N
generalized JJ N
estimating NN N
equations NNS N
. . N

Experimental JJ N
studies NNS N
of IN N
prevention NN N
programs NNS N
often RB N
randomize VBP N
clusters NNS N
of IN N
individuals NNS N
rather RB N
than IN N
individuals NNS N
to TO N
treatment NN N
conditions NNS N
. . N

When WRB N
the DT N
correlation NN N
among IN N
individuals NNS N
within IN N
clusters NNS N
is VBZ N
not RB N
accounted VBN N
for IN N
in IN N
statistical JJ N
analysis NN N
, , N
the DT N
standard JJ N
errors NNS N
are VBP N
biased VBN N
, , N
potentially RB N
resulting VBG N
in IN N
misleading VBG N
conclusions NNS N
about IN N
the DT N
significance NN N
of IN N
treatment NN N
effects NNS N
. . N

This DT N
study NN N
demonstrates VBZ N
the DT N
generalized JJ N
estimating NN N
equations NNS N
( ( N
GEE NNP N
) ) N
method NN N
, , N
focusing VBG N
specifically RB N
on IN N
the DT N
GEE-independent NNP N
method NN N
, , N
to TO N
control VB N
for IN N
within-cluster JJ N
correlation NN N
in IN N
regression NN N
models NNS N
with IN N
either DT N
continuous JJ N
or CC N
binary JJ N
outcomes NNS N
. . N

The DT N
GEE-independent JJ N
method NN N
yields NNS N
consistent JJ N
and CC N
robust JJ N
variance NN N
estimates NNS N
. . N

Data NNS N
from IN N
project NN N
DARE NNP N
, , N
a DT N
youth NN 1_p
substance NN 4_p
abuse NN 4_p
prevention NN 4_p
program NN 4_p
, , N
are VBP N
used VBN N
for IN N
illustration NN N
. . N

-DOCSTART- -X- O O 24075141

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS 4_p
diagnosed VBN 4_p
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 16167234

after IN 4_p
digestive JJ 4_p
surgery NN 4_p
] NN 4_p
digestive JJ 4_p
surgery NN 4_p
patients NNS 4_p
. . 4_p

Forty NNP 3_p
patients NNS 4_p
who WP 4_p
underwent VBP 4_p
digestive JJ 4_p
surgery NN 4_p
digestive JJ 4_p
surgery NN 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 12477021

Thirty-five JJ 3_p
university NN 4_p
students NNS 4_p
were VBD 4_p
assessed VBN 4_p
-DOCSTART- -X- O O 21491990

chronic JJ 4_p
periodontitis NN 4_p
: : 4_p
Twenty-four JJ 3_p
patients NNS 4_p
presenting VBG N
with IN N
≥12 NNP N
teeth NNS N
with IN N
probing VBG N
depth NN N
( ( N
PD NNP N
) ) N
≥5 VBP N
mm NN N
and CC N
bleeding NN N
on IN N
probing VBG N
treatment NN N
of IN N
chronic JJ N
periodontitis NN N
-DOCSTART- -X- O O 6421395

middle JJ 1_p
aged VBN 1_p
men NNS 1_p
. . 1_p

31 CD 3_p
healthy JJ 4_p
middle NNS 1_p
aged VBN 1_p
men NNS 1_p
healthy JJ 4_p
middle NN 1_p
aged VBN 1_p
men NNS 1_p
-DOCSTART- -X- O O 24317958

root JJ N
canal JJ N
Fifty-three NNP 3_p
root NN 4_p
canals NNS 4_p
with IN 4_p
two CD 4_p
standardized JJ 4_p
grooves NNS 4_p
in IN 4_p
the DT 4_p
apical JJ 4_p
and CC 4_p
coronal JJ 4_p
parts NNS 4_p
of IN 4_p
longitudinally RB 4_p
split VBN 4_p
roots NNS 4_p
-DOCSTART- -X- O O 21106663

Participants NNS N
were VBD N
236 CD 3_p
heavy JJ 4_p
drinking NN 4_p
smokers NNS 4_p
-DOCSTART- -X- O O 23549581

patients NNS 4_p
with IN 4_p
chemotherapy-induced JJ 4_p
painful JJ 4_p
peripheral JJ 4_p
neuropathy NN 4_p
: : 4_p
231 CD 3_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
25 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
being VBG N
treated VBN 4_p
at IN 4_p
community NN 4_p
and CC 4_p
academic JJ 4_p
settings NNS 4_p
between IN 4_p
April NNP 4_p
2008 CD 4_p
and CC 4_p
March NNP 4_p
2011 CD 4_p
. . N

grade VBN 4_p
1 CD 4_p
or CC 4_p
higher JJR 4_p
sensory NN 4_p
neuropathy JJ 4_p
according VBG 4_p
to TO 4_p
the DT 4_p
NCI NNP 4_p
Common NNP 4_p
Terminology NNP 4_p
Criteria NNP 4_p
for IN 4_p
Adverse NNP 4_p
Events NNS 4_p
and CC 4_p
at IN 4_p
least JJS 4_p
4 CD 4_p
on IN 4_p
a DT 4_p
scale NN 4_p
of IN 4_p
0 CD 4_p
to TO 4_p
10 CD 4_p
, , 4_p
representing VBG 4_p
average JJ 4_p
chemotherapy-induced JJ 4_p
pain NN 4_p
, , 4_p
after IN 4_p
paclitaxel NN 4_p
, , 4_p
other JJ 4_p
taxane NN 4_p
, , 4_p
or CC 4_p
oxaliplatin JJ 4_p
treatment NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
painful JJ 4_p
chemotherapy-induced JJ 4_p
peripheral JJ 4_p
neuropathy NN 4_p
-DOCSTART- -X- O O 10070173

seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . 4_p

seasonal JJ N
allergic JJ N
rhinitis NN N
( ( N
SAR NNP N
) ) N
. . N

Ontario NNP N
, , N
Quebec NNP N
and CC N
Manitoba NNP N
. . N

Two CD 3_p
hundred VBD 3_p
and CC 3_p
eighty-four JJ 3_p
out-patients NNS 4_p
with IN N
SAR NNP 4_p
, , N
who WP N
were VBD N
symptomatic JJ 4_p
during IN 4_p
the DT 4_p
ragweed NN 4_p
season NN 4_p
, , N
volunteered VBD N
for IN N
enrolment NN N
( ( N
243 CD 3_p
randomized VBN N
) ) N
. . N

SAR NNP 4_p
. . 4_p

-DOCSTART- -X- O O 12709693

outpatient JJ 4_p
colonoscopy NN 4_p
. . 4_p

for IN N
colonoscopy NN N
100 CD 3_p
adult NN 1_p
patients NNS 1_p
colonoscopy NN N
-DOCSTART- -X- O O 6989377

95 CD 3_p
patients NNS 3_p
with IN 3_p
atherosclerotic JJ 3_p
disease NN 3_p
. . N

-DOCSTART- -X- O O 16505427

anemic JJ 4_p
patients NNS 4_p
with IN 4_p
cancer NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
cancer-associated JJ 4_p
anemia NN 4_p
. . 4_p

Three CD 3_p
hundred VBD 3_p
sixty-five JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 3081600

outpatients NNS 4_p
with IN 4_p
a DT 4_p
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
. . 4_p

outpatients NNS 4_p
with IN 4_p
primary JJ 4_p
depression NN 4_p
-DOCSTART- -X- O O 23849147

status NN 4_p
epilepticus NN 4_p
. . 4_p

status NN N
epilepticus NN N
720 CD 3_p
unique JJ N
patients NNS 4_p
in IN 4_p
emergency NN 4_p
departments NNS 4_p
and CC 4_p
uses VBZ 4_p
a DT 4_p
Bayesian JJ 4_p
adaptive JJ 4_p
design NN 4_p
. . N

-DOCSTART- -X- O O 9481998

temporomandibular JJ 4_p
joint NN 4_p
pain NN 4_p
. . 4_p

temporomandibular NN N
( ( N
TMJ NNP N
) ) N
joint NN N
pain NN N
Twenty NNP 3_p
subjects NNS 4_p
, , 4_p
who WP 4_p
have VBP 4_p
TMJ NNP 4_p
pain NN 4_p
, , N
were VBD N
included VBN N
for IN N
this DT N
study NN N
-DOCSTART- -X- O O 6951573

One CD 3_p
hundred CD 3_p
and CC 3_p
twenty JJ 3_p
patients NNS 4_p
presenting VBG 4_p
at IN 4_p
Macquarie NNP 4_p
Hospital NNP 4_p
for IN 4_p
admission NN 4_p
psychiatric JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 18229990

autism NN 4_p
: : 4_p
preschool NN 1_p
children NNS 1_p
with IN 4_p
autism NN 4_p
Participants NNS N
were VBD N
58 CD 3_p
children NNS 1_p
( ( N
46 CD 3_p
boys NNS N
) ) N
with IN N
autism NN 4_p
between IN 1_p
3 CD 1_p
and CC 1_p
4 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . N

young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 14763035

left JJ 4_p
ventricular JJ 4_p
hypertrophy NN 4_p
patients NNS 4_p
on IN 4_p
continuous JJ 4_p
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
( ( 4_p
CAPD NNP 4_p
) ) 4_p
. . 4_p

24 CD 3_p
CAPD NNP 4_p
patients NNS 4_p
with IN 4_p
LVH NNP 4_p
[ NNP 4_p
left VBD 4_p
ventricular JJ 4_p
mass NN 4_p
index NN 4_p
( ( 4_p
LVMi NNP 4_p
) ) 4_p
> VBD 4_p
110 CD 4_p
g/m2 NN 4_p
for IN 4_p
women NNS 4_p
and CC N
LVMi NNP 4_p
> NNP 4_p
137 CD 4_p
g/m2 NN 4_p
for IN 4_p
men NNS 4_p
] NNS N
CAPD NNP N
patients NNS N
with IN N
LVH NNP N
-DOCSTART- -X- O O 11229858

children NNS 1_p
with IN N
malaria NN 4_p
. . N

children NNS 1_p
with IN N
malaria NN 4_p
malaria NN 4_p
. . 4_p

-DOCSTART- -X- O O 3534803

United NNP 4_p
States NNPS 4_p
General NNP 4_p
surgical JJ 4_p
patients NNS 4_p
including VBG 4_p
those DT 4_p
undergoing JJ 4_p
noncardiac JJ 4_p
thoracic NN 4_p
and CC 4_p
pelvic JJ 4_p
operations NNS 4_p
who WP 4_p
were VBD 4_p
identified VBN 4_p
at IN 4_p
moderate JJ 4_p
to TO 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
postop JJ 4_p
DVT NNP 4_p
were VBD 4_p
included VBN 4_p
. . 4_p

Eight NNP 3_p
hundred VBD 3_p
and CC 3_p
eighty JJ 3_p
eight CD 3_p
patients NNS N
were VBD N
entered VBN N
into IN N
this DT N
trial NN N
and CC N
744 CD 3_p
( ( N
85 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 9816035

previously RB 4_p
untreated VBN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
-- : 4_p
a DT 4_p
previously RB 4_p
untreated VBN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
Patients NNS 4_p
had VBD 4_p
to TO 4_p
have VB 4_p
histologically RB 4_p
documented VBN 4_p
measurable JJ 4_p
breast NN 4_p
cancer NN 4_p
and CC 4_p
a DT 4_p
performance NN 4_p
status NN 4_p
of IN 4_p
0-1 NNP 4_p
. . 4_p

Patients NNS 4_p
could MD 4_p
not RB 4_p
have VB 4_p
had VBN 4_p
prior JJ 4_p
chemotherapy NN 4_p
for IN 4_p
metastatic JJ 4_p
disease NN 4_p
. . 4_p

Prior NNP 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
was VBD 4_p
permitted VBN 4_p
. . 4_p

Patients NNS 4_p
could MD 4_p
not RB 4_p
have VB 4_p
visceral JJ 4_p
crisis NN 4_p
. . 4_p

-DOCSTART- -X- O O 18337284

group NN N
A NNP N
beta-haemolytic JJ 4_p
streptococcal JJ 4_p
pharyngitis NN 4_p
. . 4_p

GABHS NNP N
pharyngitis NN N
. . N

school-based JJ 4_p
clinic NN 4_p
in IN 4_p
New NNP 4_p
Zealand NNP 4_p
. . N

Children NNP 1_p
presenting VBG N
with IN N
GABHS NNP 4_p
pharyngitis NN 4_p
353 CD 3_p
children NNS 4_p
with IN 4_p
positive JJ 4_p
throat NN 4_p
swabs NN 4_p
for IN 4_p
GABHS NNP 4_p
GABHS NNP 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
pharyngitis NN 4_p
. . 4_p

-DOCSTART- -X- O O 10934569

children NNS 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
. . N

Young NNP 1_p
children NNS 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
( ( N
7 CD 3_p
with IN N
autism NN 4_p
, , N
8 CD 3_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
not RB 4_p
otherwise RB 4_p
specified VBN 4_p
-- : 4_p
NOS NNP 4_p
) ) N
( ( N
7 CD 3_p
with IN 4_p
autism NN 4_p
, , N
6 CD 3_p
with IN 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
NOS NNP 4_p
) ) N
Children NNP 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
NOS NNP N
autism NN N
. . N

-DOCSTART- -X- O O 11495215

nonsmokers NNS N
. . N

Sixty NNP 3_p
healthy JJ 4_p
women NNS 4_p
, , 4_p
half NN 4_p
of IN 4_p
whom WP 4_p
had VBD 4_p
been VBN 4_p
using VBG 4_p
OCs NNP 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
the DT 4_p
previous JJ 4_p
6 CD 4_p
months NNS 4_p
two CD 4_p
thirds NNS 4_p
were VBD 4_p
smokers NNS 4_p
One CD 4_p
third WDT 4_p
were VBD 4_p
nonsmokers NNS 4_p
. . 4_p

women NNS N
. . N

nonsmoking JJ N
women NNS N
-DOCSTART- -X- O O 20189026

patients NNS 4_p
with IN 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
ST-elevation NNP N
myocardial JJ N
infarction NN N
333 CD 3_p
consecutive JJ 4_p
adult NN 4_p
patients NNS 4_p
with IN 4_p
a DT 4_p
suspected VBN 4_p
first JJ 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
82 CD 3_p
patients NNS 4_p
were VBD 4_p
excluded VBN 4_p
on IN 4_p
arrival NN 4_p
at IN 4_p
hospital NN 4_p
because IN 4_p
they PRP 4_p
did VBD 4_p
not RB 4_p
meet VB 4_p
inclusion NN 4_p
criteria NNS 4_p
, , 4_p
32 CD 3_p
were VBD 4_p
lost VBN 4_p
to TO 4_p
follow-up NN 4_p
, , 4_p
and CC 4_p
77 CD 3_p
did VBD 4_p
not RB 4_p
complete VB 4_p
the DT 4_p
follow-up JJ 4_p
-DOCSTART- -X- O O 15133359

biventricular JJ 4_p
implantation NN 4_p
procedures NNS N
. . N

Thirty-four JJ 3_p
consecutive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 22435114

children NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
anxiety NN 4_p
: : N
Fifty NNP 3_p
children NNS 1_p
with IN N
high-functioning JJ 4_p
ASD NNP 4_p
and CC 4_p
anxiety NN 4_p
RESULTS NNP N
Forty-seven JJ 3_p
children NNS 1_p
completed VBN N
either CC N
the DT N
CBT NNP N
or CC N
TAU NNP N
condition NN N
for IN N
children NNS N
with IN N
ASD NNP N
-DOCSTART- -X- O O 21975269

3790 CD 3_p
heterosexual JJ 4_p
HIV-1-serodiscordant JJ 4_p
couples NNS 4_p
participating VBG 4_p
in IN 4_p
two CD 4_p
longitudinal JJ 4_p
studies NNS 4_p
of IN 4_p
HIV-1 NNP 4_p
incidence NN 4_p
in IN 4_p
seven CD 4_p
African JJ 4_p
countries NNS 4_p
. . N

Among IN N
1314 CD 3_p
couples NNS 4_p
in IN 4_p
which WDT 4_p
the DT 4_p
HIV-1-seronegative JJ 4_p
partner NN 4_p
was VBD N
female JJ 2_p
p=0·03 NN N
) ) N
. . N

Among IN N
2476 CD N
couples NNS N
in IN N
which WDT N
the DT N
HIV-1-seronegative JJ N
partner NN N
-DOCSTART- -X- O O 23392542

early-stage JJ 4_p
diabetic JJ 4_p
nephropathy JJ 4_p
patients NNS 4_p
diabetic JJ N
nephropathy NN N
Type NNP 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
( ( N
N.=57 NNP 3_p
) ) N
were VBD N
divided VBN N
Diabetic NNP 4_p
nephropathy JJ 4_p
patients NNS 4_p
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus JJ 4_p
patients NNS 4_p
" VBP N
with IN N
nephropathy JJ N
" NN N
patients NNS 4_p
with IN N
nephropathy JJ N
-DOCSTART- -X- O O 8911222

drug-free JJ 4_p
adults NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

drug-free JJ 4_p
adult NN 4_p
patients NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
. . 4_p

Twenty NNP 3_p
drug-free JJ 4_p
adults NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
( ( N
16 CD 3_p
men NNS 3_p
and CC 3_p
4 CD 3_p
women NNS 3_p
) ) N
( ( N
mean JJ 1_p
[ NNP 1_p
+/- NN 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
30.5 CD 1_p
+/- JJ 1_p
8.5 CD 1_p
years NNS 1_p
) ) N
patients NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 19159999

patients NNS 4_p
with IN 4_p
primary JJ 4_p
Raynaud NNP 4_p
's POS 4_p
phenomenon NN 4_p
in IN 4_p
South NNP 4_p
Korea NNP 4_p
; : 4_p
primary JJ N
Raynaud NNP N
's POS N
phenomenon NN N
( ( N
RP NNP N
) ) N
in IN N
Korea NNP N
. . N

Ninety-three JJ 3_p
subjects NNS 3_p
primary JJ N
RP NNP N
in IN N
Korean JJ 4_p
patients NNS 4_p
. . 4_p

primary JJ N
RP NNP 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 20618920

patients NNS 4_p
with IN 4_p
depression NN 4_p
: : 4_p
Eighty NNP 3_p
depressed VBD 4_p
patients NNS 4_p
undergoing VBG 4_p
standard JJ 4_p
antidepressant JJ 4_p
treatment NN 4_p
-DOCSTART- -X- O O 25369243

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
both DT N
ASD NNP 4_p
and CC 4_p
attention-deficit/hyperactivity JJ 4_p
disorder NN 4_p
( ( 4_p
ADHD NNP 4_p
) ) 4_p
. . N

97 CD 3_p
patients NNS N
6-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
with IN N
ASD NNP 4_p
and CC 4_p
ADHD NNP 4_p
-DOCSTART- -X- O O 23838728

children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

children NNS 4_p
with IN 4_p
autism NN 4_p
47 CD 3_p
teachers NNS 1_p
and CC 1_p
children NNS 1_p
-DOCSTART- -X- O O 7844976

School JJ 4_p
districts NNS 4_p
-DOCSTART- -X- O O 10763172

after IN 4_p
nose JJ 4_p
surgery NN 4_p
61 CD 3_p
inpatients NNS 4_p
with IN 4_p
the DT 4_p
diagnosis NN 4_p
Rhinitis NNP 4_p
following VBG 4_p
nasal JJ 4_p
operation NN 4_p
patients NNS 4_p
following VBG 4_p
nasal JJ 4_p
operations NNS 4_p
rhinitis NN 4_p
following VBG 4_p
nasal JJ 4_p
operation NN 4_p
-DOCSTART- -X- O O 2803397

ear JJ 4_p
surgery NN 4_p
ear JJ 4_p
microsurgical JJ 4_p
operations NNS 4_p
. . 4_p

Simple JJ 4_p
mastoidectomies NNS 4_p
, , 4_p
radical JJ 4_p
mastoidectomies NNS 4_p
and CC 4_p
tympano NN 4_p
plastics NNS 4_p
were VBD N
carried VBN N
out IN N
in IN N
49 CD 3_p
patients NNS N
-DOCSTART- -X- O O 22744141

preschool JJ 1_p
children NNS 1_p
who WP 4_p
have VBP 4_p
intellectual JJ 4_p
disabilities NNS 4_p
. . 4_p

preschool NN 4_p
children NNS 4_p
with IN 4_p
intellectual JJ 4_p
disabilities NNS 4_p
( ( 4_p
IDs NNP 4_p
) ) 4_p
, , 4_p
including VBG 4_p
children NNS 4_p
with IN 4_p
Down NNP 4_p
syndrome NN 4_p
and CC 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

Seventy-seven JJ 3_p
children NNS 1_p
preschool JJ 4_p
children NNS 4_p
who WP 4_p
have VBP 4_p
ID NNP 4_p
and CC 4_p
significant JJ 4_p
language NN 4_p
impairments NNS 4_p
. . 4_p

-DOCSTART- -X- O O 12576806

endopyelotomy NN N
A NNP N
total NN N
of IN N
57 CD 3_p
consecutive JJ N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
ureteropelvic JJ 4_p
junction NN 4_p
obstruction NN 4_p
endopyelotomy NN N
-DOCSTART- -X- O O 17897478

asthma NN N
. . N

patients NNS 4_p
with IN 4_p
asthma JJ 4_p
poorly RB N
controlled VBN N
on IN N
low JJ N
dose NN N
inhaled JJ N
corticosteroids NNS N
adult NN 1_p
asthmatics NNS 4_p
. . 4_p

Sixty-six JJ 3_p
subjects NNS 3_p
-DOCSTART- -X- O O 17293018

patients NNS 4_p
with IN 4_p
C. NNP 4_p
difficile-associated JJ 4_p
diarrhea NN 4_p
( ( 4_p
CDAD NNP 4_p
) ) 4_p
77 CD 3_p
patients NNS 4_p
with IN 4_p
CDAD NNP 4_p
patients NNS 4_p
with IN 4_p
CDAD NNP 4_p
. . 4_p

individuals NNS 4_p
with IN 4_p
CDAD NNP 4_p
-DOCSTART- -X- O O 23417625

children NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
: : N
young JJ N
people NNS N
with IN N
HFA NNP N
. . N

Eligible JJ N
patients NNS N
were VBD N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
HFA NNP 4_p
. . N

-DOCSTART- -X- O O 19096921

children NNS 1_p
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . N

-DOCSTART- -X- O O 10912743

treated JJ 4_p
hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

hypertensive JJ 4_p
patients NNS 4_p
receiving VBG 4_p
drug NN 4_p
treatment NN 4_p
hypertensives NNS N
on IN N
chronic NN N
, , N
stable JJ N
antihypertensive JJ N
therapy NN N
. . N

people NNS 4_p
with IN 4_p
one CD 4_p
or CC 4_p
more JJR 4_p
cardiovascular JJ 4_p
risk NN 4_p
factors NNS 4_p
. . 4_p

Fifteen NNP N
Italian JJ N
hypertension NN 4_p
units NNS N
studied VBD N
142 CD 3_p
hypertensive JJ 4_p
patients NNS N
( ( N
76 CD 3_p
men NNS 3_p
, , N
66 CD 3_p
women NNS 3_p
; : N
mean JJ 1_p
age NN 1_p
59 CD 1_p
+/- JJ 1_p
5.9 CD 1_p
years NNS 1_p
) ) N
treated VBD 4_p
with IN 4_p
different JJ 4_p
antihypertensive JJ 4_p
drugs NNS 4_p
: : N
hypertensives NNS N
under IN N
treatment NN N
. . N

-DOCSTART- -X- O O 21718094

in IN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
( ( 4_p
T1D NNP 4_p
) ) 4_p
in IN N
24 CD 3_p
patients NNS N
, , N
8-18 CD 1_p
years NNS 1_p
old JJ 1_p
, , N
with IN N
newly RB 4_p
diagnosed VBN 4_p
T1D NNP 4_p
-DOCSTART- -X- O O 17616069

postpartum NN 4_p
anemia NN N
pospartal JJ N
anemia NN N
Prague NNP 4_p
Prague NNP 4_p
. . N

50 CD 3_p
women NNS 2_p
with IN N
clinical JJ 4_p
and CC 4_p
lab JJ 4_p
signs NNS 4_p
of IN 4_p
postpartal JJ 4_p
anemia NN 4_p
. . N

pospartal JJ N
anemia NN N
-DOCSTART- -X- O O 18783504

smoking VBG N
cessation NN N
. . N

Madison NNP 4_p
, , 4_p
WI NNP 4_p
, , 4_p
USA NNP 4_p
. . N

403 CD 3_p
adult NN 4_p
, , 4_p
daily JJ 4_p
smokers NNS 4_p
without IN 4_p
contraindications NNS 4_p
to TO 4_p
bupropion VB 4_p
SR NNP 4_p
use NN 4_p
. . N

-DOCSTART- -X- O O 19108790

breast NN 4_p
cancer NN 4_p
surgery NN 4_p
: : 4_p
Japanese JJ 4_p
patients NNS 4_p
. . 4_p

breast NN 4_p
cancer NN 4_p
surgery NN 4_p
in IN 4_p
Japanese JJ 4_p
patients NNS 4_p
. . 4_p

Japanese JJ 4_p
women NNS 4_p
A DT N
total NN N
of IN N
100 CD 3_p
women NNS N
( ( N
mean JJ 1_p
[ NNP 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
52 CD 1_p
[ NN 1_p
7 CD 1_p
] CD 1_p
years NNS 1_p
; : N
height VBD 4_p
, , 4_p
154 CD 4_p
[ NN 4_p
6 CD 4_p
] NNP 4_p
cm NN 4_p
; : N
weight NN 4_p
, , 4_p
54 CD 4_p
[ NN 4_p
7 CD 4_p
] NNP 4_p
kg NN 4_p
) ) N
Japanese JJ N
women NNS N
who WP N
underwent VBP N
breast NN N
cancer NN N
surgery NN N
. . N

-DOCSTART- -X- O O 11737955

the DT 1_p
60-year-old JJ 1_p
older JJR 1_p
adults NNS 1_p
( ( 1_p
60 CD 1_p
( ( 1_p
SE NNP 1_p
1 CD 1_p
) ) 1_p
years NNS 1_p
; : 1_p
BMI NNP 1_p
26 CD 1_p
( ( 1_p
SE NNP 1_p
1 CD 1_p
) ) 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
. . N

60-year-old JJ 1_p
subjects NNS 1_p
-DOCSTART- -X- O O 16295154

parents NNS 1_p
of IN 1_p
children NNS 1_p
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

Parents NNS 1_p
of IN 1_p
children NNS 1_p
who WP N
receive VBP N
the DT N
diagnosis NN 4_p
of IN 4_p
autistic JJ 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
parents NNS 4_p
of IN 4_p
children NNS 4_p
with IN 4_p
ASD NNP 4_p
-DOCSTART- -X- O O 18544974

school-aged JJ 1_p
children NNS 1_p
school-aged JJ N
children NNS N
. . N

30 CD 3_p
healthy JJ 4_p
children NNS N
. . N

-DOCSTART- -X- O O 25950425

patients NNS 4_p
undergoing VBG 4_p
laparatomy NN 4_p
. . 4_p

patients NNS N
undergoing VBG N
laparotomy NN N
. . N

Eighty NNP 3_p
patients NNS N
( ( N
18 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) N
undergoing VBG 4_p
elective JJ 4_p
laparotomy NN 4_p
nausea NN N
in IN N
patients NNS N
undergoing VBG N
laparotomy NN N
relief NN N
in IN N
patients NNS N
undergoing VBG N
laparatomy NN N
-DOCSTART- -X- O O 3919804

insulin NN 4_p
dependent NN 4_p
diabetes VBZ 4_p
mellitus NNS 4_p
: : 4_p
45 CD 3_p
type NN 4_p
I PRP 4_p
( ( 4_p
insulin JJ 4_p
dependent NN 4_p
) ) 4_p
diabetics NNS 4_p
without IN 4_p
proliferative JJ 4_p
retinopathy NN 4_p
-DOCSTART- -X- O O 9229602

acute JJ 4_p
allergic JJ 4_p
conjunctivitis NN 4_p
] NNP 4_p
69 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 1780092

pain-inflammatory JJ N
pathologies NNS N
of IN N
the DT N
ear NN N
, , N
nose RB N
, , N
and CC N
throat NN N
] NN N
98 CD 3_p
patients NNS N
aged VBN 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
75 CD 1_p
suffering VBG N
from IN N
pain-inflammatory JJ 4_p
pathologies NNS 4_p
of IN 4_p
ENT NNP 4_p
nature NN 4_p
. . 4_p

-DOCSTART- -X- O O 8989009

in IN N
the DT 1_p
elderly JJ 1_p
: : N
in IN N
elderly JJ 1_p
patients NNS 1_p
. . N

Eighty-five JJ 3_p
ASA NNP 4_p
grade NN 4_p
I PRP 4_p
or CC 4_p
II NNP 4_p
patients NNS 4_p
( ( 4_p
aged VBN 4_p
60-89 CD 4_p
yr NN 4_p
) ) 4_p
for IN 4_p
elective JJ 4_p
total JJ 4_p
hip NN 4_p
replacement NN 4_p
elderly JJ 1_p
patients NNS 1_p
undergoing VBG 4_p
elective JJ 4_p
procedures NNS 4_p
-DOCSTART- -X- O O 26278470

Obsessive-Compulsive NNP 4_p
Disorder NNP 4_p
with IN 4_p
Poor NNP 4_p
Insight NNP 4_p
: : 4_p
poor-insight JJ N
OCD NNP N
. . N

patients NNS 4_p
with IN 4_p
OCD NNP 4_p
with IN 4_p
poor JJ 4_p
insight NN 4_p
. . 4_p

90 CD 3_p
patients NNS 4_p
with IN 4_p
OCD NNP 4_p
with IN 4_p
poor JJ 4_p
insight NN 4_p
Patients NNPS 4_p
with IN 4_p
OCD NNP 4_p
with IN 4_p
poor JJ 4_p
insight JJ 4_p
patients NNS N
with IN N
more RBR N
extreme JJ N
poor JJ N
insight NN N
. . N

-DOCSTART- -X- O O 21914768

Male JJ 2_p
students NNS 4_p
( ( N
N=443 NNP 3_p
) ) N
-DOCSTART- -X- O O 361799

advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

600 CD 3_p
cases NNS 3_p
advanced JJ 4_p
breast NN 4_p
cancers NNS 4_p
in IN 4_p
eight CD 4_p
French JJ 4_p
anticancer NN 4_p
centres NNS 4_p
. . N

603 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 17321989

patients NNS 4_p
with IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
and CC 4_p
myelodysplastic JJ 4_p
syndromes NNS 4_p
: : 4_p
Japanese JJ 4_p
patients NNS 4_p
with IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
( ( 4_p
AML NNP 4_p
) ) 4_p
or CC 4_p
myelodysplastic JJ 4_p
syndromes NNS 4_p
( ( 4_p
MDS NNP 4_p
) ) 4_p
during IN 4_p
and CC 4_p
after IN 4_p
chemotherapy NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
AML NNP 4_p
or CC 4_p
MDS NNP 4_p
who WP 4_p
received VBD 4_p
chemotherapy NN 4_p
-DOCSTART- -X- O O 10578479

premenopausal JJ 4_p
women NNS 2_p
. . 4_p

36 CD 3_p
premenopausal JJ 4_p
women NNS 2_p
, , N
20 CD 3_p
of IN N
whom WP N
used VBD 4_p
OC NNP 4_p
. . N

premenopausal NN 4_p
OC NNP 4_p
or CC N
non-OC JJ 4_p
users NNS 4_p
. . 4_p

-DOCSTART- -X- O O 24080592

patients NNS 4_p
with IN 4_p
isolated JJ 4_p
hypertriglyceridemia NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
isolated JJ 4_p
hypertriglyceridemia NN 4_p
. . 4_p

39 CD 3_p
patients NNS 4_p
with IN 4_p
elevated JJ 4_p
triglyceride NN 4_p
levels NNS 4_p
and CC 4_p
peripheral JJ 4_p
artery NN 4_p
sclerosis NN 4_p
fibrinolysis NN N
in IN N
patients NNS N
with IN N
isolated JJ N
hypertriglyceridemia NN N
benefits NNS N
to TO N
patients NNS N
with IN N
elevated JJ N
triglyceride NN N
levels NNS N
-DOCSTART- -X- O O 8726604

outpatient JJ 4_p
surgery NN 4_p
. . 4_p

47 CD 3_p
healthy JJ 4_p
women NNS 2_p
undergoing VBG 4_p
elective JJ 4_p
ambulatory NN 4_p
surgery NN 4_p
. . N

women NNS 2_p
-DOCSTART- -X- O O 23114870

patients NNS 4_p
undergoing VBG 4_p
minimally RB 4_p
invasive JJ 4_p
TKA NNP 4_p
80 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 10940525

dogs NNS 4_p
and CC 4_p
cats NNS 4_p
presented VBD 4_p
as IN 4_p
veterinary JJ 4_p
patients NNS 4_p
in IN 4_p
North NNP 4_p
America NNP 4_p
. . 4_p

on IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
showing VBG 4_p
signs NNS 4_p
of IN 4_p
flea NN 4_p
allergy NN 4_p
dermatitis NN 4_p
( ( 4_p
FAD NNP 4_p
) ) 4_p
. . 4_p

Dogs NNS 4_p
and CC 4_p
cats NNS 4_p
with IN 4_p
naturally RB 4_p
occurring VBG 4_p
flea NN 4_p
infestations NNS 4_p
, , 4_p
some DT 4_p
of IN 4_p
which WDT 4_p
also RB 4_p
had VBD 4_p
signs NNS 4_p
associated VBN 4_p
with IN 4_p
FAD NNP 4_p
( ( N
220 CD 3_p
dogs NNS 3_p
, , 3_p
189 CD 3_p
cats NNS 3_p
) ) N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
diagnosed VBD 4_p
clinically RB 4_p
with IN 4_p
FAD NNP 4_p
. . 4_p

397 CD 3_p
dogs NNS 4_p
free JJ 4_p
of IN 4_p
adult NN 4_p
heartworm NN 4_p
infection NN 4_p
from IN 4_p
four CD 4_p
heartworm-endemic JJ 4_p
areas NNS 4_p
of IN 4_p
the DT 4_p
USA NNP 4_p
673 CD 3_p
dogs NNS 3_p
and CC 3_p
347 CD 3_p
cats NNS 3_p
having VBG N
an DT N
age NN N
range NN N
of IN N
6 CD N
weeks NNS N
to TO N
19 CD N
years NNS N
19 CD 3_p
purebred VBD 4_p
or CC 4_p
crossbred JJ 4_p
Collies NNS 4_p
( ( 4_p
Bearded NNP 4_p
, , 4_p
Border NNP 4_p
, , 4_p
and CC 4_p
unspecified JJ 4_p
) ) 4_p
. . 4_p

in IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
. . 4_p

-DOCSTART- -X- O O 23985254

postoperative JJ 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
adjuvant JJ 4_p
concurrent NN 4_p
chemoradiotherapy NN 4_p
] NNP 4_p
postoperative JJ 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
who WP 4_p
received VBD 4_p
capecitabine-based JJ 4_p
postoperative JJ 4_p
chemoradiotherapy NN 4_p
( ( 4_p
CRT NNP 4_p
) ) 4_p
. . 4_p

Four CD 3_p
hundred VBD 3_p
patients NNS 4_p
with IN 4_p
stage NN 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
rectal JJ 4_p
cancer NN 4_p
received VBD 4_p
postoperative JJ 4_p
CRT NNP 4_p
postoperative JJ 4_p
stage NN 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 10390665

children NNS 1_p
. . 1_p

tonsillectomy NN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
adenoidectomy NN 4_p
in IN N
children NNS 1_p
. . N

90 CD 3_p
paediatric JJ 1_p
patients NNS 1_p
, , N
ASA NNP 1_p
I PRP 1_p
, , N
aged VBN 1_p
4-10 CD 1_p
years NNS 1_p
children NNS 1_p
undergoing VBG 1_p
general JJ 1_p
anaesthesia NN 1_p
for IN 4_p
tonsillectomy NN 4_p
. . N

-DOCSTART- -X- O O 24660757

Compensation NN N
in IN N
intergroup JJ N
relations NNS N
: : N
an DT N
investigation NN N
of IN N
its PRP$ N
structural JJ N
and CC N
strategic JJ N
foundations NNS N
. . N

Recent JJ N
work NN N
in IN N
intergroup JJ N
relations NNS N
stresses VBZ N
the DT N
role NN N
of IN N
two CD N
fundamental JJ N
dimensions NNS N
, , N
competence NN N
and CC N
warmth NN N
, , N
which WDT N
organize VBP N
the DT N
perception NN N
of IN N
social JJ N
groups NNS N
. . N

A DT N
pattern NN N
often RB N
encountered VBN N
in IN N
people NNS N
's POS N
ratings NNS N
is VBZ N
one CD N
of IN N
compensation NN N
in IN N
that DT N
a DT N
group NN N
that WDT N
is VBZ N
evaluated VBN N
higher JJR N
than IN N
another DT N
group NN N
on IN N
one CD N
of IN N
the DT N
two CD N
fundamental JJ N
dimensions NNS N
is VBZ N
also RB N
judged VBN N
lower JJR N
on IN N
the DT N
other JJ N
fundamental JJ N
dimension NN N
. . N

Based VBN N
on IN N
Social NNP N
Identity NNP N
Theory NNP N
, , N
the DT N
present JJ N
work NN N
extends VBZ N
previous JJ N
research NN N
on IN N
compensation NN N
by IN N
examining VBG N
boundary JJ N
conditions NNS N
as RB N
well RB N
as IN N
underlying VBG N
psychological JJ N
processes NNS N
. . N

Two CD N
studies NNS N
involving VBG N
experimental JJ N
and CC N
correlational JJ N
evidence NN N
, , N
minimal JJ N
and CC N
real JJ N
groups NNS N
, , N
and CC N
different JJ N
kinds NNS N
of IN N
conflict NN N
, , N
reveal NN N
that IN N
compensation NN N
is VBZ N
more RBR N
likely JJ N
when WRB N
the DT N
groups NNS N
are VBP N
in IN N
asymmetrical JJ N
relation NN N
and CC N
share NN N
a DT N
cooperative JJ N
view NN N
of IN N
the DT N
intergroup NN N
setting NN N
. . N

Our PRP$ N
data NNS N
also RB N
suggest VBP N
that IN N
, , N
among IN N
members NNS N
of IN N
low JJ N
status NN N
groups NNS N
, , N
compensation NN N
is VBZ N
associated VBN N
with IN N
social JJ N
creativity NN N
. . N

In IN N
contrast NN N
, , N
and CC N
in IN N
line NN N
with IN N
the DT N
'noblesse NNP N
oblige NN N
' '' N
effect NN N
, , N
members NNS N
of IN N
the DT N
high JJ N
status NN N
group NN N
would MD N
seem VB N
to TO N
rely VB N
on IN N
compensation NN N
as IN N
a DT N
means NN N
to TO N
appear VB N
non-discriminatory JJ N
. . N

-DOCSTART- -X- O O 384815

Three CD 3_p
hundred VBD 3_p
forty-one NN 3_p
Tanzanian JJ 4_p
preschool NN 1_p
children NNS 1_p
-DOCSTART- -X- O O 21669557

Guatemala NNP N
49 CD 3_p
intervention NN N
and CC N
70 CD 3_p
control NN N
women NNS N
38-84 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
and CC N
55 CD 3_p
control NN N
subjects NNS N
were VBD N
also RB N
assessed VBN N
after IN N
receiving VBG N
stoves NNS N
. . N

-DOCSTART- -X- O O 11317090

persons NNS 4_p
with IN 4_p
osteoarthritis NN 4_p
. . 4_p

249 CD 3_p
adults NNS 1_p
from IN 4_p
Washington NNP 4_p
State NNP 4_p
aged VBD 1_p
55 CD 1_p
to TO 1_p
75 CD 1_p
with IN N
a DT N
doctor-confirmed JJ 4_p
diagnosis NN 4_p
of IN 4_p
osteoarthritis NN 4_p
to TO N
participate VB N
in IN N
aquatic JJ N
classes NNS N
. . N

-DOCSTART- -X- O O 11750293

recent JJ 4_p
onset NN 4_p
rheumatoid NN 4_p
arthritis NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
recently RB 4_p
diagnosed VBN 4_p
rheumatoid NN 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
Twenty-two JJ 3_p
patients NNS 4_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
recently RB 4_p
diagnosed VBN 4_p
RA NNP 4_p
of IN 4_p
less JJR 4_p
than IN 4_p
2 CD 4_p
years NNS 4_p
22 CD 3_p
patients NNS 3_p
recent JJ N
onset NN N
RA NNP N
. . N

-DOCSTART- -X- O O 11099086

acute JJ 4_p
invasive JJ 4_p
diarrhea NN 4_p
in IN N
children NNS 1_p
. . N

Acute NNP N
invasive JJ N
diarrhea NN N
in IN N
children NNS 1_p
. . 1_p

acute JJ N
invasive JJ N
diarrhea NN N
requiring VBG N
an DT N
emergency NN N
visit NN N
in IN N
southern JJ N
Israel NNP N
. . N

invasive JJ N
diarrhea NN N
. . N

acute JJ 4_p
invasive JJ 4_p
diarrhea NN 4_p
in IN N
infants NNS 1_p
and CC 1_p
children NNS 1_p
. . N

201 CD 3_p
evaluable JJ N
children NNS 1_p
ages VBZ 1_p
6 CD 1_p
months NNS 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
( ( 1_p
35 CD 1_p
% NN 1_p
< CC 1_p
1 CD 1_p
year NN 1_p
; : 1_p
70 CD 1_p
% NN 1_p
< JJ 1_p
3 CD 1_p
years NNS 1_p
) ) 1_p
presenting VBG 4_p
with IN 4_p
acute JJ 4_p
invasive JJ 4_p
diarrhea NN 4_p
at IN 4_p
the DT 4_p
Pediatric NNP 4_p
Emergency NNP 4_p
Room NNP 4_p
acute JJ N
invasive JJ N
diarrhea NN N
in IN N
ambulatory JJ 4_p
pediatric JJ 4_p
patients NNS 4_p
requiring VBG 4_p
an DT 4_p
emergency NN 4_p
room NN 4_p
visit NN 4_p
. . 4_p

-DOCSTART- -X- O O 22897461

in IN N
patients NNS 4_p
with IN 4_p
mixed JJ 4_p
dyslipidaemia NN 4_p
and CC 4_p
metabolic JJ 4_p
syndrome NN 4_p
in IN N
patients NNS 4_p
with IN 4_p
mixed JJ 4_p
dyslipidaemia NN 4_p
and CC 4_p
MetS NNP 4_p
study NN N
, , N
only RB N
patients NNS 4_p
with IN 4_p
MetS NNP 4_p
were VBD N
included VBN N
-DOCSTART- -X- O O 11891832

inclusion NN 4_p
body NN 4_p
myositis NN 4_p
44 CD 3_p
patients NNS 4_p
with IN 4_p
inclusion NN 4_p
body NN 4_p
myositis NN 4_p
-DOCSTART- -X- O O 19708562

patients NNS 4_p
with IN 4_p
gastric JJ 4_p
ulcer JJ 4_p
] NN 4_p
100 CD 3_p
patients NNS 4_p
with IN 4_p
gastric JJ 4_p
ulcer NNS 4_p
aged VBN 1_p
from IN 1_p
16 CD 1_p
to TO 1_p
60 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 26210844

Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
in IN N
Toddlers NNP 1_p
. . N

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
in IN N
toddlers NNS 1_p
toddlers NNS 4_p
with IN 4_p
ASD NNP 4_p
from IN 4_p
toddlers NNS 4_p
with IN 4_p
developmental JJ 4_p
delay NN 4_p
( ( 4_p
DD NNP 4_p
) ) 4_p
/non-ASD NN 4_p
in IN 4_p
an DT 4_p
early JJ 4_p
childhood NN 4_p
clinic NN 4_p
. . 4_p

toddlers NNS 1_p
with IN 4_p
no DT 4_p
developmental JJ 4_p
concerns NNS 4_p
. . 4_p

A DT 3_p
total NN 3_p
of IN 3_p
61 CD 3_p
toddlers NNS 3_p
were VBD N
enrolled VBN N
. . N

ASD NNP 4_p
in IN 4_p
toddlers NNS 4_p
-DOCSTART- -X- O O 25898782

retrograde NN 4_p
cholangiopancreatography NN 4_p
: : 4_p
study NN N
included VBD N
281 CD 3_p
adults NNS 1_p
in IN N
301 CD N
procedures NNS N
. . N

-DOCSTART- -X- O O 15014018

Nearly RB 3_p
2000 CD 3_p
patients NNS 4_p
with IN 4_p
stage NN 4_p
IIB NNP 4_p
and CC 4_p
III NNP 4_p
melanoma NNS 4_p
patients NNS 4_p
with IN 4_p
high-risk JJ 4_p
resected JJ 4_p
melanoma NN 4_p
-DOCSTART- -X- O O 24451919

ADHD NNP 4_p
and CC 4_p
Autism NNP 4_p
. . 4_p

Attention NNP 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
( ( 4_p
ADHD NNP 4_p
) ) 4_p
and CC 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
Age-matched JJ N
boys NNS N
with IN N
ADHD NNP N
( ( N
15 CD 3_p
) ) N
, , N
ASD NNP N
( ( N
18 CD 3_p
) ) N
, , N
and CC N
controls NNS N
( ( N
21 CD 3_p
) ) N
-DOCSTART- -X- O O 18077611

subjects NNS 1_p
> VBP 1_p
or CC 1_p
=50 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

Subjects VBZ 4_p
with IN 4_p
a DT 4_p
negative JJ 4_p
history NN 4_p
for IN 4_p
HZ NNP 4_p
Enrollment NN 1_p
was VBD 1_p
stratified VBN 1_p
1:2 CD 1_p
by IN 1_p
age NN 1_p
( ( 1_p
50 CD 1_p
to TO 1_p
59 CD 1_p
years NNS 1_p
and CC 1_p
> NN 1_p
or CC 1_p
=60 CD 1_p
years NNS 1_p
) ) 1_p
-DOCSTART- -X- O O 6938020

prostatic JJ 4_p
cancer NN 4_p
. . 4_p

previously RB 4_p
untreated JJ 4_p
patients NNS 4_p
with IN 4_p
prostatic JJ 4_p
cancer NN 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
disease NN 4_p
no RB 4_p
longer RBR 4_p
responsive VB 4_p
to TO 4_p
hormonal JJ 4_p
treatment NN 4_p
-DOCSTART- -X- O O 12139812

pterygium NN 4_p
] NN N
pterygium NN 4_p
. . 4_p

208 CD 3_p
patients NNS 3_p
( ( N
229 CD N
eyes NNS N
) ) N
with IN N
initial JJ 4_p
pterygium NN 4_p
pterygium NN N
. . N

-DOCSTART- -X- O O 9695300

acute JJ 4_p
bronchiolitis NN 4_p
. . 4_p

One CD 3_p
hundred CD 3_p
and CC 3_p
fifty-six JJ 3_p
infants NNS 1_p
aged VBN 1_p
between IN 1_p
7 CD 1_p
weeks NNS 1_p
and CC 1_p
24 CD 1_p
months NNS 1_p
who WP N
had VBD N
had VBN 4_p
an DT 4_p
episode NN 4_p
of IN 4_p
wheezing NN 4_p
and CC 4_p
other JJ 4_p
signs NNS 4_p
and CC 4_p
symptoms NNS 4_p
of IN 4_p
bronchiolitis NN 4_p
acute JJ N
bronchiolitis NN N
. . N

-DOCSTART- -X- O O 2224060

acute JJ 4_p
nonlymphocytic JJ 4_p
leukemia NN 4_p
in IN N
adults NNS 1_p
. . N

adult NN 1_p
acute JJ 4_p
nonlymphocytic JJ 4_p
leukemia NN 4_p
( ( 4_p
ANLL NNP 4_p
) ) 4_p
The DT N
101 CD 3_p
eligible JJ N
cases NNS N
( ( N
bestatin NN N
: : N
48 CD 3_p
, , N
control NN N
: : N
53 CD 3_p
) ) N
